Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith W Pratz

Showing results (21-30 of 73) with videos related to

Pageof 8
Sort By:
Blood Advances|April 29, 2021
Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysisDavid J Young, Bao Nguyen, Ruiqi Zhu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2017
Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological MalignanciesShailly Mehrotra, Mathangi Gopalakrishnan, Jogarao Gobburu, et al.
Leukemia Research|January 21, 2014
Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitroRobert L Dilley, Weijie Poh, Douglas E Gladstone, et al.
Journal of Palliative Medicine|May 25, 2017
A Single Center Survey of Health-Related Quality of Life among Acute Myeloid Leukemia Survivors in First Complete RemissionM Jennifer Cheng, B Douglas Smith, Christopher S Hourigan, et al.
Molecular Diagnosis & Therapy|October 9, 2015
A Novel Tandem Duplication Assay to Detect Minimal Residual Disease in FLT3/ITD AMLMing-Tseh Lin, Li-Hui Tseng, Jonathan C Dudley, et al.
Clinical and Translational Science|April 28, 2018
Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 RelationshipTao Liu, Vijay Ivaturi, Philip Sabato, et al.
Blood|November 26, 2008
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical responseKeith W Pratz, Jorge Cortes, Gail J Roboz, et al.
Cancer Research|September 20, 2017
Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other MalignanciesJ Kyle Bruner, Hayley S Ma, Li Li, et al.
Scientific Reports|March 7, 2019
Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivoNicole D Vincelette, Husheng Ding, Amelia M Huehls, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2022
Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and AzacitidineDaniel A Pollyea, Keith W Pratz, Andrew H Wei, et al.
Pageof 8

Showing results (21-30 of 73) with videos related to

Sort By:
Pageof 8
Blood Advances|April 29, 2021
Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysisDavid J Young, Bao Nguyen, Ruiqi Zhu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2017
Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological MalignanciesShailly Mehrotra, Mathangi Gopalakrishnan, Jogarao Gobburu, et al.
Leukemia Research|January 21, 2014
Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitroRobert L Dilley, Weijie Poh, Douglas E Gladstone, et al.
Journal of Palliative Medicine|May 25, 2017
A Single Center Survey of Health-Related Quality of Life among Acute Myeloid Leukemia Survivors in First Complete RemissionM Jennifer Cheng, B Douglas Smith, Christopher S Hourigan, et al.
Molecular Diagnosis & Therapy|October 9, 2015
A Novel Tandem Duplication Assay to Detect Minimal Residual Disease in FLT3/ITD AMLMing-Tseh Lin, Li-Hui Tseng, Jonathan C Dudley, et al.
Clinical and Translational Science|April 28, 2018
Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 RelationshipTao Liu, Vijay Ivaturi, Philip Sabato, et al.
Blood|November 26, 2008
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical responseKeith W Pratz, Jorge Cortes, Gail J Roboz, et al.
Cancer Research|September 20, 2017
Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other MalignanciesJ Kyle Bruner, Hayley S Ma, Li Li, et al.
Scientific Reports|March 7, 2019
Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivoNicole D Vincelette, Husheng Ding, Amelia M Huehls, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2022
Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and AzacitidineDaniel A Pollyea, Keith W Pratz, Andrew H Wei, et al.
Pageof 8